Exact Sciences Corporation [NASDAQ:EXAS]: Analyst Rating and Earnings
Experts stock market traders frequently make a point to check what top Wall Street analysts say regarding a potential buy. Regarding Exact Sciences Corporation [EXAS] currently, the latest Wall Street ratings we can see is from the fiscal quarter that’s going to end in December. On average, stock market experts give EXAS an Outperform rating. Its stock price has been found in the range of 47.78 to 111.70. This is compared to its latest closing price of $110.20.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Exact Sciences Corporation [EXAS] is sitting at 1.54. This is compared to 1 month ago, when its average rating was 1.54.
For the quarter ending in Mar-19 Exact Sciences Corporation [EXAS] generated $0.16 billion in sales. That’s 5.88% higher than the average estimate of $0.15 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Stay on the lookout for the next publication of this organization’s financial results for the quarter, which will be made public on Wed 7 Aug (In 55 Days).
Fundamental Analysis of Exact Sciences Corporation [EXAS]
Now let’s turn to look at profitability: with a current Operating Margin for Exact Sciences Corporation [EXAS] sitting at -35.09 and its Gross Margin at +74.04, this company’s Net Margin is now -41.60%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -16.77, and its Return on Invested Capital has reached -11.60%. Its Return on Equity is -29.16, and its Return on Assets is -16.50. These metrics suggest that this Exact Sciences Corporation does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Exact Sciences Corporation [EXAS] has generated a Total Debt to Total Equity ratio of 102.30. Similarly, its Total Debt to Total Capital is 50.57, while its Total Debt to Total Assets stands at 45.71. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 102.30, and its Long-Term Debt to Total Capital is 50.57. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.
What about valuation? This company’s Enterprise Value to EBITDA is -99.17. The Enterprise Value to Sales for this firm is now 25.70, and its Total Debt to Enterprise Value stands at 0.10. Exact Sciences Corporation [EXAS] has a Price to Book Ratio of 11.42.
Shifting the focus to workforce efficiency, Exact Sciences Corporation [EXAS] earns $229,875 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 11.81 and its Total Asset Turnover is 0.43. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 8.70 and its Current Ratio is 8.99. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Exact Sciences Corporation [EXAS] has 124.37M shares outstanding, amounting to a total market cap of $13.96B. Its stock price has been found in the range of 47.78 to 111.70. At its current price, it has moved by 0.52% from its 52-week high, and it has moved 134.99% from its 52-week low.
This stock’s Beta value is currently 1.62, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 70.36. This RSI suggests that Exact Sciences Corporation is currently Overbought.
Conclusion: Is Exact Sciences Corporation [EXAS] a Reliable Buy?
Shares of Exact Sciences Corporation [EXAS], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.